{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:43:56Z","timestamp":1771929836099,"version":"3.50.1"},"reference-count":36,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF2010-17083"],"award-info":[{"award-number":["SAF2010-17083"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2016,2,25]]},"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1136\/ejhpharm-2015-000853","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T18:42:55Z","timestamp":1462473775000},"page":"343-347","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of bevacizumab quality and stability in repackaged syringes for clinical use"],"prefix":"10.1136","volume":"23","author":[{"given":"A","family":"Santove\u00f1a","sequence":"first","affiliation":[{"name":"Instituto de Enfermedades Tropicales y Salud P\u00fablica de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"S\u00e1nchez-Negr\u00edn","sequence":"additional","affiliation":[{"name":"Instituto de Enfermedades Tropicales y Salud P\u00fablica de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Nazco","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JB","family":"Fari\u00f1a","sequence":"additional","affiliation":[{"name":"Instituto de Enfermedades Tropicales y Salud P\u00fablica de Canarias, Universidad de La Laguna, La Laguna, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"2025090221262753000_23.6.343.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31871-8"},{"key":"2025090221262753000_23.6.343.2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v2.i6.98"},{"key":"2025090221262753000_23.6.343.3","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"2025090221262753000_23.6.343.4","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225766.75009.3a"},{"key":"2025090221262753000_23.6.343.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"2025090221262753000_23.6.343.6","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3180654240"},{"key":"2025090221262753000_23.6.343.7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.10.1357"},{"key":"2025090221262753000_23.6.343.8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318198148e"},{"key":"2025090221262753000_23.6.343.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.023"},{"key":"2025090221262753000_23.6.343.10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10792-015-0043-0","article-title":"The safety of bevacizumab and ranibizumab in clinical studies","volume":"5","author":"De Rosa","year":"2015","journal-title":"Int Ophthalmol"},{"key":"2025090221262753000_23.6.343.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2025090221262753000_23.6.343.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2025090221262753000_23.6.343.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"2025090221262753000_23.6.343.14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"2025090221262753000_23.6.343.15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00417-014-2641-3","article-title":"The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters","volume":"252","author":"Elshout","year":"2014","journal-title":"Graefes Arch Clin Ophthalmol"},{"key":"2025090221262753000_23.6.343.16","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20150101-10"},{"key":"2025090221262753000_23.6.343.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"2025090221262753000_23.6.343.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0754-7"},{"key":"2025090221262753000_23.6.343.19","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181bd2d51"},{"key":"2025090221262753000_23.6.343.20","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181baf691"},{"key":"2025090221262753000_23.6.343.21","unstructured":"Medicines and Healthcare Products Regulatory Agency 2012. Company-led drug recall: Bevacizumab Intravitreal Injection 1.25 mg\/0.05ml - Moorfields Pharmaceuticals - CLDA(12)A\/04. http:\/\/trove.nla.gov.au\/work\/163636137?versionId=178402218 (accessed Dec 2015)."},{"key":"2025090221262753000_23.6.343.22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/eye.2009.7","article-title":"Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection","volume":"23","author":"Artunay","year":"2009","journal-title":"Eye"},{"key":"2025090221262753000_23.6.343.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.035"},{"key":"2025090221262753000_23.6.343.24","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.180729"},{"key":"2025090221262753000_23.6.343.25","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0076"},{"key":"2025090221262753000_23.6.343.26","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318217ffde"},{"key":"2025090221262753000_23.6.343.27","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.139"},{"key":"2025090221262753000_23.6.343.28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6431"},{"key":"2025090221262753000_23.6.343.29","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d50cea"},{"key":"2025090221262753000_23.6.343.30","first-page":"21","article-title":"Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration","volume":"101","author":"Paul","year":"2012","journal-title":"Ann Pharm Fr"},{"key":"2025090221262753000_23.6.343.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0270(01)00443-5"},{"key":"2025090221262753000_23.6.343.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.01.025"},{"key":"2025090221262753000_23.6.343.33","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225354.92444.7a"},{"key":"2025090221262753000_23.6.343.34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201015666140619120834","article-title":"Quantification, microbial contamination, physic-chemical stability of repackaged bevacizumab stored under different conditions","volume":"15","author":"Signorello","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"key":"2025090221262753000_23.6.343.35","unstructured":"ICH Q2(R1), 2014, in: The International Conference on Harmonisation. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf (accessed Mar 2016)."},{"key":"2025090221262753000_23.6.343.36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chroma.2014.04.027","article-title":"Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability \u00edndices","volume":"353","author":"Oliva","year":"2014","journal-title":"J Chromatogr A"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2015-000853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:26:34Z","timestamp":1756873594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2015-000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,10,27]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1136\/ejhpharm-2015-000853"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2015-000853","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}